| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.006 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.082 | 0.006 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.006 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.007 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.008 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.13 | 0.009 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | 0.09 | 0.01 |
| mRNA | MK-2206 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.01 |